AngioDynamics, Inc. filed a Form 8-K on November 18, 2026, disclosing the voting results from its Annual Meeting of Shareholders held on November 17, 2026, including the election of two Class II directors, ratification of its auditor, approval of executive compensation on an advisory basis, and approval of an amended equity incentive plan.

Key Highlights

  • Director elections: Eileen O. Auen received 28,252,245 votes for and Jan Stern Reed received 27,956,254 votes for, each elected as a Class II director to serve until the 2029 Annual Meeting.
  • Auditor ratified: Deloitte & Touche LLP was ratified as independent registered public accounting firm for the fiscal year ending May 31, 2027, with 36,287,806 votes in favor.
  • Say-on-pay approved: The advisory vote on named executive officer compensation passed with 29,073,414 votes for and 1,691,653 votes against.
  • Equity plan amended: Shareholders approved the amended 2020 Equity Incentive Plan with 26,990,852 votes for and 3,784,918 votes against, increasing shares available for issuance.
  • Broker non-votes: 5,872,140 broker non-votes were recorded for the director elections, say-on-pay, and equity plan proposals.

AngioDynamics 2026 Annual Meeting: Election, Auditor, and Equity Plan Outcomes

According to the filing, AngioDynamics (NASDAQ:ANGO) held its Annual Meeting of Shareholders on November 17, 2026. Two nominees stood for election as Class II directors: Eileen O. Auen, who received 28,252,245 votes for and 2,555,472 withheld, and Jan Stern Reed, who received 27,956,254 votes for and 2,851,463 withheld. Both were elected to serve until the 2029 Annual Meeting and until their respective successors are duly elected and qualified, the filing stated.

The company disclosed that shareholders ratified the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2027. That proposal received 36,287,806 votes for approval, 381,289 votes against, and 10,762 abstentions, with no broker non-votes reported for that item. The advisory vote to approve executive compensation of named executive officers passed with 29,073,414 votes for, 1,691,653 votes against, 42,650 abstentions, and 5,872,140 broker non-votes.

Shareholders also voted to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan, which the filing described as increasing the number of shares available for issuance. That proposal received 26,990,852 votes for, 3,784,918 votes against, 31,947 abstentions, and 5,872,140 broker non-votes. The filing noted that the material terms of the 2020 Plan were described in Proposal 4 of AngioDynamics' definitive proxy statement filed with the SEC on October 8, 2026, and that the full text of the plan is attached as Exhibit 10.1 to the current report.

What Was Disclosed

AngioDynamics reported the shareholder vote outcomes from its November 17, 2026 Annual Meeting, covering director elections, auditor ratification, an advisory compensation vote, and approval of an amended equity incentive plan that increases shares available for issuance.